2 weeks Ago By ABMN Staff
Federated Hermes Inc. lowered its stake in shares of Nevro Corp. ( NYSE:NVRO – Free Report ) by 77.
2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 55,679 shares of the medical equipment provider’s stock after selling 188,515 shares during the quarter.
Federated Hermes Inc.’s holdings in Nevro were worth $207,000 at the end of the most recent quarter. Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company.
Amundi purchased a new position in shares of Nevro during the fourth quarter valued at $30,000. Headlands Technologies LLC acquired a new position in shares of Nevro in the 4th quarter valued at $45,000. Ieq Capital LLC purchased a new position in Nevro during the 4th quarter worth approximately $46,000.
Virtu Financial LLC purchased a new position in shares of Nevro during the 3rd quarter valued at about $63,000. Finally, SG Americas Securities LLC increased its holdings in shares of Nevro by 34.6% during the 4th quarter.
SG Americas Securities LLC now owns 17,126 shares of the medical equipment provider’s stock valued at $64,000 after purchasing an additional 4,406 shares in the last quarter. 95.52% of the stock is owned by hedge funds and other institutional investors.
Nevro Trading Up 0.1 % Shares of NVRO stock opened at $5.85 on Friday.
Nevro Corp. has a twelve month low of $3.17 and a twelve month high of $13.
30. The company has a market capitalization of $224.32 million, a P/E ratio of -3.
09 and a beta of 0.81. The company has a current ratio of 5.
02, a quick ratio of 3.76 and a debt-to-equity ratio of 0.67.
The business’s 50 day moving average is $5.79 and its two-hundred day moving average is $5.01.
Analyst Upgrades and Downgrades A number of equities analysts have weighed in on NVRO shares. Piper Sandler upgraded shares of Nevro from a “neutral” rating to an “overweight” rating and reduced their price objective for the stock from $6.00 to $5.
85 in a research report on Friday, February 7th. Canaccord Genuity Group boosted their price target on shares of Nevro from $4.00 to $5.
85 and gave the company a “hold” rating in a research note on Friday, February 7th. StockNews.com assumed coverage on shares of Nevro in a report on Tuesday.
They set a “hold” rating on the stock. Finally, Jefferies Financial Group upgraded shares of Nevro from an “underperform” rating to a “hold” rating and raised their price objective for the company from $4.50 to $5.
85 in a report on Monday, February 10th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.
com, the company currently has a consensus rating of “Hold” and a consensus target price of $5.36. Get Our Latest Research Report on NVRO Nevro Profile ( Free Report ) Nevro Corp.
, a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. See Also Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Nevro Corp. ( NYSE:NVRO – Free Report ). Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.
com's FREE daily email newsletter ..
